Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma
ContributorsPouleau, Blandine; Estoppey, Carole; Suere, Perrine; Nallet, Emilie; Laurendon, Amélie; Monney, Thierry ; Pais Ferreira, Daniela ; Drake, Adam; Carretero-Iglesia, Laura; Macoin, Julie; Berret, Jérémy; Pihlgren, Maria; Doucey, Marie-Agnès; Gudi, Girish S; Menon, Vinu; Udupa, Venkatesha; Maiti, Abhishek; Borthakur, Gautam; Srivastava, Ankita ; Blein, Stanislas ; Mbow, M Lamine; Matthes, Thomas; Kaya, Zeynep ; Edwards, Claire M; Edwards, James R; Menoret, Emmanuelle; Kervoëlen, Charlotte; Pellat-Deceunynck, Catherine; Moreau, Philippe; Zhukovsky, Eugene; Perro, Mario ; Chimen, Myriam
Published inBlood, vol. 142, no. 3, p. 260-273
Publication date2023-07-20
Abstract
Keywords
- Animals
- Mice
- ADP-ribosyl Cyclase 1 / metabolism
- Antibodies, Bispecific / pharmacology
- Antibodies, Bispecific / therapeutic use
- Multiple Myeloma / drug therapy
- T-Lymphocytes / pathology
Citation (ISO format)
POULEAU, Blandine et al. Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma. In: Blood, 2023, vol. 142, n° 3, p. 260–273. doi: 10.1182/blood.2022019451
Main files (1)
Article (Published version)
Secondary files (1)
Identifiers
- PID : unige:170572
- DOI : 10.1182/blood.2022019451
- PMID : 37192303
ISSN of the journal0006-4971